Baird maintained an Outperform rating and $346.00 price target on Intercept Pharmaceuticals (NASDAQ: ICPT) following the company's announcement that the ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst Comments

Consensus Needs to Come Down on Intercept (ICPT) after FDA Review is Extended - LeerinkDecember 18, 2015 8:44 AM After-Hours Stock Movers 12/17: (RHT) (DLTH) (RMBS) Higher; (KNX) (ICPT) (VTAE) Lower (more...)December 17, 2015 6:06 PM Intercept Pharma (ICPT) Announces PDUFA Date Extension for OCA in PBCDecember 17, 2015 5:01 PM FDA Extends PDUFA Date for Obeticholic Acid for the Treatment of PBCDecember 17, 2015 5:00 PM Streetinsider.com's Hot Lunchtime Reads 12/16: (FCEL) (V) (ICPT) (VRX) (MBLY)December 16, 2015 11:58 AM FBR & Co. Still Sidelined on Intercept Pharma (ICPT) Amid M&A Chatter; Sees Takeout Around $192/ShareDecember 16, 2015 11:55 AM